Mole Mapping London: NHS vs Private Cost & Benefits

Two Different Questions, Not Two Prices for One Service

The comparison people expect is cost. The more useful comparison is what each route is designed to answer.

Read that way, “NHS or private” is the wrong framing for most people. If you have a lesion that has changed, the NHS route is both free and fast and is the right choice. If you have eighty moles and nothing in particular is wrong, the NHS has nothing to offer you, and no amount of asking will change that.

What the NHS Does Provide

The urgent suspected-cancer pathway

A GP who judges a lesion suspicious refers it urgently, and it moves fast. Across London, 95.2% of patients start treatment within 31 days of a decision to treat. Referral is guided by NICE NG12, which includes a weighted seven-point checklist — change in size, irregular shape and irregular colour score two points each, with diameter of 7 mm or more scoring one. Worth noting that diameter, the feature patients weigh most heavily, is the weakest signal on the list.

Assessment and removal of a lesion that meets criteria

Including histology and, where melanoma is confirmed, management through a skin cancer multidisciplinary team. That MDT requirement is national, and no private clinic manages melanoma outside one.

Structured follow-up after a melanoma

Under NICE NG14, with the interval and duration set by stage. If you have had a melanoma, you are already in a surveillance system, and it runs in parallel with anything private you arrange.

Routine dermatology

For non-urgent lesions. This is where the wait sits: between 45% and 56% of routine dermatology patients wait more than 18 weeks depending on the London region, and 38.8% in Hertfordshire and West Essex.

What It Does Not Provide, and Why

No baseline photography, no annual imaging, and no surveillance for someone who has never had a melanoma — however many moles they have.

The reasoning is worth understanding rather than resenting. Population screening programmes are adopted where a trial has shown they reduce mortality. For skin cancer, that evidence does not exist: no randomised controlled trial has shown that screening or photographic surveillance reduces melanoma mortality. Being straightforward about that cuts both ways — it explains the NHS position, and it is also the honest limit of what a private service can claim.

What can be defended is narrower and still worth something: sequential imaging supports detection at a lower Breslow thickness, and thickness at diagnosis determines the width of the definitive excision, whether a sentinel lymph node biopsy is offered, and the outlook. That is the argument for mapping, and it is the whole of it.

Who Is Actually Better Off Paying

Mapping is a risk-stratified service, not something everyone should buy. It earns its cost where there is enough to track that memory and attention are unreliable:

• More than roughly 50 to 100 moles, or a significant number of clinically atypical ones
• Atypical mole syndrome, or a known CDKN2A mutation or FAMMM kindred
• A previous melanoma — though note this group is already in NHS follow-up, so the question is whether to add imaging to it rather than whether to have anything at all
• A first-degree relative with melanoma, particularly diagnosed young
• Fitzpatrick I–II skin, marked freckling, blistering sunburn history or sunbed use
• Immunosuppression, including after organ transplant
• Practical inability to self-examine — extensive naevi on the back, poor vision, or nobody to check for you

Equally honest is the inverse. Someone with a handful of ordinary moles, no atypical lesions, no family history and no immunosuppression is well served by regular self-examination and a low threshold for asking. The full weighting is in who is at high risk of melanoma.

The Money, Stated Plainly

Two things people are not usually told before booking. Around 20% of patients who attend for a map have something removed, so the removal and histology lines are a realistic possibility rather than a remote one. And the value of a first map does not arrive on the day: at baseline there is nothing to compare against, so the comparison function — which is the service — begins at the second visit.

Insurance does not usually close the gap. Most UK policies exclude screening and preventive services, so a routine map on an asymptomatic patient is self-pay, while diagnostic investigation of a lesion that is changing is often covered. The awkward consequence is a policy declining the map and then covering the excision the map produced — set out in mole screening and health insurance. Full breakdown of what the £300 includes: mole mapping cost.

If Paying Is Not an Option

The gap is real, and there are things that genuinely help without £300.

1. Self-examine with method rather than diligence. Same lighting, same order, monthly, comparing against your own previous photographs rather than judging each mole afresh — checking your own skin.
2. Photograph properly. Consistent distance and lighting, a ruler or coin in frame for scale, repeated monthly. That produces a record worth bringing to an appointment, which is a different thing from a diagnosis.
3. Get someone to look at your back. The sites patients miss are not the risky ones, they are the unseen ones.
4. Go to the GP with the lesion, not the request. “This mole has changed shape and colour over three months” is a referral conversation. “I would like mole mapping” is a request the NHS cannot fulfil.

And do not substitute an app for any of this. A phone photograph does not capture the subsurface structures a diagnosis rests on, and a reassuring score carries no information — see mole-check apps versus clinical examination.

Frequently Asked Questions

Is mole mapping available on the NHS?

No. The UK has no population screening programme for skin cancer, so baseline photography and annual imaging of an asymptomatic patient are not NHS services. The NHS pathway is diagnostic: it assesses a specific lesion that already meets referral criteria.

Why does the NHS not offer it?

Because no randomised trial has shown that screening or photographic surveillance reduces melanoma mortality, and screening programmes are adopted on that evidence. It is a considered position rather than a funding oversight.

Can I ask my GP to refer me for mole mapping?

A GP can refer a specific lesion that meets NICE NG12 criteria, and should. There is no NHS referral route for whole-skin photographic surveillance, so a request framed that way cannot be actioned however reasonable it is.

If something looks suspicious, is the NHS slower than going private?

Not for urgent cases. Across London 95.2% of patients start treatment within 31 days of a decision to treat, and paying does not move a genuinely urgent case forward. Where private care changes the timeline is routine dermatology, where 45% to 56% of London patients wait over 18 weeks.

What does private mole mapping cost?

£300 for the complete package, and £300 for each subsequent annual map — there is no repeat discount. Removal, if something is found, is £350, with histology at £180 where the lesion warrants it.

Will insurance cover it?

Usually not. Most UK policies exclude screening and preventive services, so a routine map is self-pay. Diagnostic investigation of a lesion that is changing or symptomatic is often covered, subject to policy, referral and pre-authorisation.

I have had a melanoma. Do I need to pay for surveillance?

You should already be in NHS follow-up under NICE NG14, with the interval set by stage. The question is whether to add photographic imaging to that, not whether you have surveillance at all — and it is worth discussing with the team already following you.

Is it worth £300 if I am not high risk?

For a few stable moles with no family history and no immunosuppression, it is a reasonable choice but not a clinical necessity, and it should be described that way rather than sold. Regular self-examination and a low threshold for review is a defensible alternative.